Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum

More articles from Diabetes and the Kidney

  • Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease
    Open Access
    Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease
    John P. Hanrahan, Ian H. de Boer, George L. Bakris, Phebe J. Wilson, James D. Wakefield, Jelena P. Seferovic, Jennifer G. Chickering, Yueh-tyng Chien, Kenneth Carlson, Michael D. Cressman, Mark G. Currie, G. Todd Milne and Albert T. Profy
    CJASN January 2021, 16 (1) 59-69; DOI: https://doi.org/10.2215/CJN.08410520
    Add to Selected Citations
  • Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury
    You have accessRestricted Access
    Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury
    Min Zhao, Shusen Sun, Zhenguang Huang, Tiansheng Wang and Huilin Tang
    CJASN January 2021, 16 (1) 70-78; DOI: https://doi.org/10.2215/CJN.11220720
    Add to Selected Citations
  • Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN)
    You have accessRestricted Access
    Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN)
    Sadayoshi Ito, Naoki Kashihara, Kenichi Shikata, Masaomi Nangaku, Takashi Wada, Yasuyuki Okuda and Tomoko Sawanobori
    CJASN December 2020, 15 (12) 1715-1727; DOI: https://doi.org/10.2215/CJN.06870520
    Add to Selected Citations
  • Effects of Canagliflozin in Patients with Baseline eGFR &lt;30 ml/min per 1.73 m<sup>2</sup>
    You have accessRestricted Access
    Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2
    George Bakris, Megumi Oshima, Kenneth W. Mahaffey, Rajiv Agarwal, Christopher P. Cannon, George Capuano, David M. Charytan, Dick de Zeeuw, Robert Edwards, Tom Greene, Hiddo J.L. Heerspink, Adeera Levin, Bruce Neal, Richard Oh, Carol Pollock, Norman Rosenthal, David C. Wheeler, Hong Zhang, Bernard Zinman, Meg J. Jardine and Vlado Perkovic
    CJASN December 2020, 15 (12) 1705-1714; DOI: https://doi.org/10.2215/CJN.10140620
    Add to Selected Citations
  • Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD
    You have accessRestricted Access
    Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD
    Flory T. Muanda, Matthew A. Weir, Lavanya Bathini, Kristin K. Clemens, Vlado Perkovic, Manish M. Sood, Eric McArthur, Jessica M. Sontrop, Richard B. Kim and Amit X. Garg
    CJASN December 2020, 15 (12) 1728-1739; DOI: https://doi.org/10.2215/CJN.08310520
    Add to Selected Citations
  • Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories
    Open Access
    Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories
    Adeera Levin, Vlado Perkovic, David C. Wheeler, Stefan Hantel, Jyothis T. George, Maximilian von Eynatten, Audrey Koitka-Weber, Christoph Wanner and on behalf of the EMPA-REG OUTCOME Investigators
    CJASN October 2020, 15 (10) 1433-1444; DOI: https://doi.org/10.2215/CJN.14901219
    Add to Selected Citations
  • Carbamylated Lipoproteins and Progression of Diabetic Kidney Disease
    You have accessRestricted Access
    Carbamylated Lipoproteins and Progression of Diabetic Kidney Disease
    Kathryn C.B. Tan, Ching-Lung Cheung, Alan C.H. Lee, Joanne K.Y. Lam, Ying Wong and Sammy W.M. Shiu
    CJASN March 2020, 15 (3) 359-366; DOI: https://doi.org/10.2215/CJN.11710919
    Add to Selected Citations
  • Sodium Bicarbonate Supplementation and Urinary TGF-<em>β</em>1 in Nonacidotic Diabetic Kidney Disease
    You have accessRestricted Access
    Sodium Bicarbonate Supplementation and Urinary TGF-β1 in Nonacidotic Diabetic Kidney Disease
    Kalani L. Raphael, Tom Greene, Guo Wei, Tristin Bullshoe, Kunani Tuttle, Alfred K. Cheung and Srinivasan Beddhu
    CJASN February 2020, 15 (2) 200-208; DOI: https://doi.org/10.2215/CJN.06600619
    Add to Selected Citations
  • Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria
    Open Access
    Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria
    Sadayoshi Ito, Kenichi Shikata, Masaomi Nangaku, Yasuyuki Okuda and Tomoko Sawanobori
    CJASN August 2019, 14 (8) 1161-1172; DOI: https://doi.org/10.2215/CJN.14751218
    Add to Selected Citations
  • Combination of Changes in Estimated GFR and Albuminuria and the Risk of Major Clinical Outcomes
    You have accessRestricted Access
    Combination of Changes in Estimated GFR and Albuminuria and the Risk of Major Clinical Outcomes
    Toshiaki Ohkuma, Min Jun, John Chalmers, Mark E. Cooper, Pavel Hamet, Stephen Harrap, Sophia Zoungas, Vlado Perkovic, Mark Woodward and on behalf of the ADVANCE Collaborative Group
    CJASN June 2019, 14 (6) 862-872; DOI: https://doi.org/10.2215/CJN.13391118
    Add to Selected Citations

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire